Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

Abstract:

-Single injection at low end of the projected therapeutic dose range

-Well tolerated based on clinical chemistry markers and clinical observation

-Additional data to be discussed at analyst event on March 25

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

Pasadena, CA | Posted on March 14th, 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus (HBV) supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens. Dr. Robert Lanford and his team at the Texas Biomedical Research Institute are conducting the study. The chimpanzee being treated has had chronic HBV for over 30 years, has high viral-titer and antigenemia, and nearly 100% of hepatocytes stain positive for HBV. Studies are ongoing and additional data will be discussed when the company hosts an analyst and investor event on March 25, and at upcoming scientific conferences.

"It's encouraging to see data from our preclinical rodent models confirmed in a true primate disease setting," said Bruce Given, MD, Arrowhead's COO and Head of R&D. "There are very few high primates that develop chronic HBV. We understand these studies to be useful predictors of the response we might expect in human patients as we approach clinical trials later this year."

Investors and analysts may access the live presentation on March 25 on the Arrowhead Research website at www.arrowheadresearch.com or by calling 1.888.771.4371 (US toll free) or 1.847.585.4405 (US toll) and using the confirmation number: 34474854. The webcast will also be available for 90 days following the event.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone
CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

National Space Society Congratulates SpaceX on the Falcon 9's Return to Flight January 19th, 2017

Eric Berger Wins the National Space Society's 2017 Space Pioneer Award for Mass Media January 19th, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Investments/IPO's/Splits

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Nanomedicine

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017

Keystone Nano Announces FDA Approval Of Investigational New Drug Application For Ceramide NanoLiposome For The Improved Treatment Of Cancer January 10th, 2017

Discoveries

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Strength of hair inspires new materials for body armor January 18th, 2017

Self-assembling particles brighten future of LED lighting January 18th, 2017

Announcements

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

National Space Society Congratulates SpaceX on the Falcon 9's Return to Flight January 19th, 2017

Eric Berger Wins the National Space Society's 2017 Space Pioneer Award for Mass Media January 19th, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Events/Classes

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016

Imec and Holst Centre Introduce World’s First Solid-State Multi-Ion Sensor for Internet-of-Things Applications December 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project